Musculoskeletal Symptoms in Post Acute Covid-19 Patients

Sponsor
Eskisehir City Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04932889
Collaborator
(none)
280
1
3
2840.8

Study Details

Study Description

Brief Summary

The patients whose musculoskeletal symptoms initiated or aggravated with Covid-19, were compared with the patients whose musculoskeletal symptoms did not change with Covid-19. The variables; the demographic and treatment datas, admission symptoms, post acute-Covid-19 symptoms, laboratory, chest computed tomography findings.

Condition or Disease Intervention/Treatment Phase
  • Other: Survey
  • Other: Laboratory parameters
  • Other: chest computed tomography

Detailed Description

There is a lack of an overview of the factors associated with post acute-Covid-19 musculoskeletal symptoms. The aims are;1-to evaluate the most frequent admission symptoms and the frequency of musculoskeletal symptoms in post acute-Covid-19 patients,2-to determine the related factors with the post acute-Covid-19 musculoskeletal symptoms.

In this retrospective study; the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19, were compared wthe patients whose musculoskeletal symptoms did not change with Covid-19. The variables; the demographic and treatment datas, admission symptoms, post acute-Covid-19 symptoms, laboratory (complete blood count, C-reactive protein, ferritin, D-dimer), chest computed tomography findings.

Study Design

Study Type:
Observational
Actual Enrollment :
280 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Musculoskeletal Symptoms and Related Factors in Post Acute Covid-19 Patients
Actual Study Start Date :
Jun 11, 2021
Actual Primary Completion Date :
Jun 13, 2021
Actual Study Completion Date :
Jun 14, 2021

Arms and Interventions

Arm Intervention/Treatment
Change

the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19 (n=240)

Other: Survey
A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.

Other: Laboratory parameters
The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.

Other: chest computed tomography
Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).

No change

the patients whose musculoskeletal symptoms did not change with Covid-19 (n=40)

Other: Survey
A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.

Other: Laboratory parameters
The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.

Other: chest computed tomography
Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).

Outcome Measures

Primary Outcome Measures

  1. Rate of back pain [Baseline]

    given as percentage %

  2. Chest computed tomography [Baseline]

    Presence of covid-19 findings in chest computed tomography (covid findings positive or negative)

  3. Rate of low-back pain [Baseline]

    given as percentage %

  4. Rate of fatigue [Baseline]

    given as percentage %

  5. Rate of neck pain [Baseline]

    given as percentage %

  6. Rate of dyspnea [baseline]

    given as percentage %

  7. Rate of joint pain [Baseline]

    given as percentage %

  8. Rate of chest pain [Baseline]

    given as percentage %

  9. Rate of myalgia [Baseline]

    given as percentage %

Secondary Outcome Measures

  1. age [Baseline]

    years

  2. Weight [Baseline]

    kilograms

  3. gender [Baseline]

    female or male

  4. Duration after the onset of covid-19 [Baseline]

    months

  5. Lymhocyte levels [Baseline]

    10*3 cells/microliter

  6. D-dimer levels [Baseline]

    miligram/Litre

  7. C-reactive protein [Baseline]

    miligram/Litre

  8. Hemoglobin [Baseline]

    gram/desilitre

  9. Platelet [Baseline]

    10*3 cells/microliter

  10. Ferritin [Baseline]

    nanogram/mililitre

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Being 18 years or older

  • Having Covid-19 treatment (home quarantine / hospital / intensive care unit) according to a positive polymerase chain reaction (PCR) test in a nasopharyngeal + oropharyngeal swab or chest CT.

Exclusion Criteria:
  • Patients who did not have musculoskeletal symptom records (admission symptoms and musculoskeletal symptoms such as; fatigue, spine / joint /muscle pain/ numbness) in patients files

  • Acute Covid-19 patients whose symptoms started less than 1 month

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eskişehir City Hospital Eskişehir Turkey

Sponsors and Collaborators

  • Eskisehir City Hospital

Investigators

  • Principal Investigator: Fulya Bakılan, Eskişehir City Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fulya Bakılan, Specialist in physical medicine and rehabilitation, Eskisehir City Hospital
ClinicalTrials.gov Identifier:
NCT04932889
Other Study ID Numbers:
  • EskisehirCityH
First Posted:
Jun 21, 2021
Last Update Posted:
Jun 21, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 21, 2021